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Abstract: Enzymatic approaches to challenges in chemical synthesis are increasingly popular and very 
attractive to industry given their green nature and high efficiency compared to traditional methods. In this 
historical review we highlight the developments across several fields that were necessary to create the modern 
field of biocatalysis, with enzyme engineering and directed evolution at its core. We exemplify the modular, 
incremental, and highly unpredictable nature of scientific discovery, driven by curiosity, and showcase the 
resulting examples of cutting-edge enzymatic applications in industry.  
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
3 
 
 
Growing up in Germany, Christian M. Heckmann studied Chemistry at the 
University of Nottingham, earning his MSci in 2017. He then started a PhD with 
Francesca Paradisi in collaboration with Johnson Matthey, studying 
biocatalytic approaches to the synthesis of chiral amines. 
 
Prof. Francesca Paradisi is the Chair of Pharmaceutical and Bioorganic 
Chemistry at the University of Bern. Biocatalysis as a sustainable approach to 
synthesis of valuable products is the focus of her research group. In particular, 
the group developed a number of enzyme-based processes in continuous flow, 
reducing the gap between academic discovery and industrial application. 
1 Introduction	
Mesophilic organisms can carry out reactions under mild conditions, enabled by excellent catalysts: enzymes. 
Humans have, unknowingly at first, used these enzymes to their advantage for millennia, for example to ferment 
sugars into alcohol (as early as 7000 BC).[1] So how did we get from biocatalysis being used unknowingly to the 
modern application at the forefront of chemical synthesis? In this review, the origin of modern biocatalysis is 
summarized (Figure 1), starting with the discovery of enzymes, and exploring the principles of biochemistry and 
molecular biology that were being developed throughout the 20th century leading to the biotechnological 
advancements at the turn of the century which resulted in increasingly sophisticated applications of enzymes, in 
particular in industry. This review aims at condensing these biological developments primarily from the point of 
view of a chemist and is primarily intended to help chemists, but also scientists from other disciplines, entering 
the field, while also showcasing selected cutting-edge applications of enzymes that may be of interest to biologists 
as well. 
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Figure 1: Timeline of major developments in enzymology, molecular biology, and biocatalysis. 
2 Early	enzymology—demystifying	life	
In 1833, diastase (a mixture of amylases) was the first enzyme to be discovered,[2] quickly followed by other 
hydrolytic enzymes such as pepsin and invertase,[3] but the term enzyme was only coined in 1877 by Wilhelm 
Kühne.[4] The concept of catalysts, chemicals facilitating a reaction without undergoing any change themselves, 
was introduced in 1836[5] by Berzelius who quickly hypothesized that enzymes were such catalysts.[6] Yeast, which 
had been observed in ethanolic fermentations, was also viewed as a catalyst, but soon it was discovered that it 
was a living organism which at the time seemed to contradict that concept.[7] Evidence from Pasteur that 
fermentation occurs in the absence of oxygen and failed attempts to isolate an enzyme able to carry out this 
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transformation, were claimed as evidence by vitalists that a “life-force” was necessary for these more complex 
transformations and that enzymes only carried out “simple” hydrolysis reactions.[8a] Indeed, this is often framed 
as a dispute between Pasteur and Liebig, with the former supporting vitalism and the latter supporting a 
mechanistic view that ascribes no special place to life. However, it appears more accurate to say that Pasteur 
supported the idea that fermentation was carried out by yeast through chemical means whereas Liebig opposed 
the idea of any causal link between yeast as a living organism and the catalytic fermentation reaction, instead 
thinking that the decay of yeast in the presence of oxygen was catalyzing the formation of alcohol from sugar.[8] 
Finally, in 1897, Eduard Büchner showed that a dead yeast extract could carry out the same fermentation reaction 
as living yeast, thus dealing the final blow to vitalism, which had already been on the decline (Nobel Prize in 
Chemistry 1907).[3,8a]  
The fermentation of sugars into ethanol and carbon dioxide was attributed to “zymase.” Further 
investigations started to reveal reaction intermediates, and dependency on phosphate and “co-zymase” (A. 
Harden and, H. von Euler-Chelpin; Nobel Prize in Chemistry 1929) and started to untangle glycolysis. However, 
the chemical nature of enzymes was still being debated. In 1926, James B. Sumner crystallized the first enzyme 
(urease), and confirmed it was a protein.[9] John H. Northrop also crystallized several other proteins, amongst 
them pepsin, trypsin, and chymotrypsin.[6] They were awarded the Nobel Prize in Chemistry in 1946; in his Nobel 
lecture,[9] Sumner remarks that  
“The organic chemist has never been able to synthesize cane sugar, but by using enzymes, the biological 
chemist can synthesize not only cane sugar but also gum dextran, gum levan, starch and glycogen.” 
Indeed, a whole range of industrial applications of mainly whole organisms but also some enzyme 
preparations had already been developed. For example, glycerol (used in the production of explosives) was 
produced on a 1000 ton per month scale in Germany during world war I, employing fermentation in yeast with 
the final acetaldehyde reduction step inhibited by sulfite, resulting in dihydroxyacetone phosphate reduction. By 
1949, citric acid was almost exclusively produced using the fungus Aspergillus niger (ca. 26,000,000 pounds per 
year in the US alone), even though it was not understood how the organism produced it.[10] In 1934, a patent was 
granted for the condensation of acetaldehyde (produced in-situ from glucose) with benzaldehyde catalyzed by 
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whole yeast, giving L-phenylacetylcarbinol, which was then further reacted to give L-ephedrine, a stimulant used 
during anesthesia, as a decongestant, and also a pre-cursor to illicit drugs such as methamphetamine (Scheme 
1).[11] This procedure is still used today, highlighting the power of an efficient biocatalytic process.[12] Enzymes 
prepared from fungi or bacteria became alternatives to those initially obtained from plants or animals (e.g. 
amylases and proteases). Purified proteases were used to clarify beer since 1911, pectinases (from various fungi 
or malt) were used to clarify juices and wine.[9b] In the early 1950s, several species of fungi were applied to the 
regio-selective hydroxylation of steroids for the production of cortisone, which had been impossible using 
chemical means.[13] 
 
Scheme 1: Synthesis of L-ephedrine: Benzoin-type addition of acetaldehyde (formed in-situ by yeast metabolism) to benzaldehyde (now 
known to be catalyzed by pyruvate decarboxylase),[14] followed by reductive amination with methylamine.[11]  
  By 1949 a vast number of enzyme classes had been discovered and characterized extensively. Many 
pathways and intermediates were fully uncovered, yet little was known with regard to the mechanism by which 
individual enzymes worked.[9b] Through the famous lock-and-key model, proposed by Emil Fischer in 1894,[15] as 
well as the Michaelis-Menten model of enzyme kinetics from 1913 (Equation 1, Figure 2)[16] it was understood 
that a substrate has to bind to the enzyme prior to catalysis, yet how this binding proceeds and how catalysis 
occurs afterwards was unsolved. The ratio of kcat/kuncat has been found to be as high as 1017, crowning enzymes 
as exceptional catalysts. Interestingly, most enzymes have similar kcat values (within two orders of magnitude), 
while the rate constants of the corresponding un-catalyzed reactions (kuncat) vary wildly.[17] 
a)									E	 + 	S	 ⇄ ES	 → 	E	 + 	P			
b)									𝑣 = 𝑣!"#[S]𝐾! + [S] = 𝑘$"%[E]&[S]𝐾! + [S]  
Equation 1: The Michaelis-Menten model and equation, in modern form: a) Enzyme and substrate combine in a reversible fashion to form 
the enzyme-substrate complex, which then goes on to release the enzyme and product in an irreversible reaction. b) Under the assumption 
of a steady state concentration of the enzyme-substrate complex, the Michaelis-Menten equation can be written, describing the 
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consumption of substrate depending on substrate concentration [S], maximum velocity vmax (itself dependent on enzyme concentration 
[E]0), and substrate affinity Km.  
 
Figure 2: Plots of the Michaelis-Menten model, illustrating equation 1. A) Velocity vs. substrate concentration under constant enzyme 
concentration. The substrate affinity Km corresponds to the substrate concentration at which the reaction reaches half of vmax, which is the 
velocity at infinite substrate concentration. B) vmax vs. enzyme concentration. The reaction is first-order with respect to enzyme 
concentration, with the rate constant kcat. 
3 Enzyme	structures	and	elucidation	of	mechanisms	
In 1948 Linus Pauling proposed that enzymes had to stabilize the transition state rather than the substrate 
as proposed by Fischer.[18] The detailed concept of a transition state itself had only been developed less than two 
decades earlier.[19] This was further refined by Koshland in 1958,[20] proposing the concept of “induced-fit,” 
explaining the specificity of enzymes on an abstract level. In parallel to this abstract understanding, a more 
detailed understanding of the structure of proteins was being developed. It had been hypothesized since the 
beginning of the 20th century that proteins were composed of chains of amino acids connected via amide 
bonds;[21] however, the order or even the relative amount of amino acids was not well understood, and indeed 
the peptide hypothesis itself was frequently questioned.[22] In 1951, Sanger determined the amino acid sequence 
(referred to as primary structure) of insulin, revealing that indeed as expected it was a well-defined sequence of 
amino acids linked by amide bonds.[23] He received his first Nobel Prize in Chemistry in 1958 for this work.  
Famously, Linus Pauling proposed how a chain of amino acids might fold into regular geometric features 
(i.e. α-helices and β-sheets; referred to as secondary structure, Figure 3) while sick in bed, based on his detailed 
understanding of the rigidity of the amide bond and “reasonable” interatomic distances. The rigorous 
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understanding of chemical bonds had just been developed for which Pauling received his Nobel Prize in Chemistry 
in 1954.[24]  
 
Figure 3: The original drawings of an α-helix (left) and parallel and anti-parallel β-sheets (right), published by Pauling in 1951, copyright 
the original authors.[24b,d] 
In the meantime, X-ray crystallography, developed from 1912 onward by Max von Laue, (Nobel Prize in 
Physics in 1914) and William and Lawrence Bragg (Nobel Prize in Physics in 1915), had become more sophisticated 
and was being applied to increasingly complex compounds. Evidence for Pauling’s secondary structure from X-
ray diffraction was reported by Max Perutz in 1951.[25] The first structures of proteins were solved in 1958-1960 
by John Kendrew and Max Perutz (Nobel Prize in Chemistry in 1962).[26] This was initially met with some degree 
of disappointment as it revealed that proteins were “messy” (Figure 4) and squashed the hope that solving the 
structure of one protein would reveal the structure of all proteins (in contrast to DNA where that expectation 
largely held true).[27] However, as higher resolution structures were obtained the insight that could be gained into 
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the mystery world of enzymes became apparent and many groups set forth to investigate not just proteins but 
enzymes (Figure 4).[28]  
 
Figure 4: Top left: Clay model of the first X-ray structure of a protein, myoglobin, at 6 Å resolution. Reprinted with permission from Springer 
Nature (ref.[26a]), copyright 1958. Right: electron density sections of myoglobin at 2 Å resolution and sketch of groups coordinated to iron. 
Reprinted with permission from Springer Nature (ref.[26b]), copyright 1960. Bottom left: Model of the catalytic triad and oxyanion hole of 
chymotrypsin, as inferred from crystal-structures. Reprinted from ref.,[31c] copyright 1970, with permission from Elsevier. 
Structures of lysozyme were solved in 1965,[29] and included structures of the enzyme with inhibitors bound 
to it, revealing the location and residues of its active site. Other enzyme structures solved around this time include 
bovine carboxypeptidase A in 1967,[30] both with and without substrate bound—revealing conformational 
changes (in agreement with the induced fit hypothesis) as well as key interactions between substrate and enzyme. 
The crystal structure of chymotrypsin (also in 1967)[31] paved the way to uncover the classic catalytic triad and 
oxyanion hole of proteases (as well as esterases and other hydrolytic enzymes; Figure 4). In 1971, the Protein 
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
10 
 
Data Bank (PDB) was founded with seven structures,[28] reaching 50 structures in 1979, and 100 structures three 
years later. At the end of 2019 it contained almost 160,000 structures.[32] 
In parallel to the increasing understanding of the structure of enzymes, newly developed physical-
chemistry techniques were also employed to elucidate mechanisms, such as detailed kinetics, isotopic labelling, 
isotope effects, and spectroscopic techniques.[33] The first mechanisms to be elucidated in that way were of 
enzymes employing co-enzymes, as the structures (fragments) of co-enzymes were determined before the 
structures of whole proteins. Indeed, as early as 1936,[34] Otto Warburg showed that certain pyridines (analogous 
to nicotinamide that could be obtained from hydrolysis “co-zymase”) could transfer hydrides reversibly, implying 
that such a hydride transfer plays a role during glycolysis (he had previously received the Nobel Prize in Physiology 
or Medicine in 1931 for his work on the role of iron in respiration).  
 
Figure 5: Selected structures of common cofactors that were known by 1955: NAD+, NADP+ and FAD are redox catalysts, ATP transfers 
energy released during glycolysis, thiamine is the co-factor of pyruvate decarboxylase during fermentation, and pyridoxal is the co-factor 
of transaminases, which are of particular industrial importance, as well as racemases, decarboxylases, and lysases involved in amino acid 
metabolism.  
The full structure of thiamine (cocarboxylase) had been proved in 1936 by Williams and Cline.[35] The 
structures of pyridoxine, as well as of biologically relevant derivatives pyridoxal and pyridoxamine were 
established in the early 1940s by Esmond Snell soon after the discovery of transaminases.[36] Full structures of 
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NAD(P)(H) (co-zymase),[37] ATP,[38] and FAD[39] were proved by Alexander Todd in the late 1940s and 50s (Nobel 
Prize in Chemistry in 1957). The structure of Vitamin B12 (cyanocobalamin) was solved through X-ray 
crystallography by Dorothy Hodgkin in 1955[40] (Figure 5; Nobel Prize in Chemistry in 1964). 
 
Figure 6: Selected mechanisms of co-factors that were being elucidated in the 1950s: enantiospecificity during hydride transfer from 
NAD(P)H in alcohol dehydrogenases, and thiamine-dependent decarboxylation.[33b]  
The chemistries of those co-factors could be investigated in the absence as well as in the presence of their 
enzymes, and from this, mechanistic details could be inferred. In addition, structural analogues could be 
synthesized and their reactivities compared. For example, careful isotope labelling studies in the early 1950s 
revealed that one hydride of the pyridine ring of NAD(P)H was transferred during reduction/oxidation in a 
stereospecific manner, giving additional detail to Otto Warburg’s mechanism (Figure 6).[41] In 1957, Breslow 
showed by NMR that an anion in position 2 of a thiazolium ring could exist, revealing the reactive center of 
thiamine (Figure 6).[42] The observation that pyridoxal, the co-factor of transaminases, as well as structural 
analogues with electron withdrawing groups on the aromatic ring, can catalyze transamination in the absence of 
the enzyme allowed Alexander Braunstein and Esmond Snell to postulate independently a likely catalytic cycle in 
1954, which later proved to be correct (Figure 7).[33b,36b,43] 
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Figure 7: Mechanism of transamination. For clarity, the individual steps of aldimine/ketimine formation and hydrolysis as well as 
transimination are not shown. The mechanism is symmetric—referred to as a “ping–pong” bi-bi or shuttle mechanism—and fully 
reversible. Note: the ketimine intermediates are a second aldimine if one of the R–groups is a hydrogen. Catalytic lysine: red; amine donor: 
blue; ketone acceptor: green. 
However, these advances in the knowledge of how enzymes work had no immediate impact on industrial 
biocatalysis, which was largely limited by the low quantities most enzymes could be obtained in. Major 
developments at the time include the application of glucose isomerase for the production of high fructose corn 
syrup (HFCS) and the development of a penicillin acylase process for the production of 6-aminopenicillanic acid 
(6-APA, at the time obtained from chemical cleavage of penicillin), a building block for semi-synthetic antibiotics 
such as ampicillin and amoxycillin (Scheme 2).[44] Key for the success of both applications was the discovery of the 
possibility to immobilize proteins with retention of their function as discovered in the 1950s.[45] This allowed the 
enzymes to be recycled and used in a continuous fashion, reducing cost by reducing the quantity of enzyme that 
has to be isolated. The HFCS processes became wide-spread in the 1970s.[46] However, the production of 6-APA 
via chemical hydrolysis predominated until the early 1990s, at least partially due to the difficulty of obtaining 
sufficient quantities of penicillin acylase before then.[47] A notable exception is Bayer, who used an immobilized 
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penicillin acylase since 1972 as a closely guarded secret, employing E. coli strains that achieved a penicillin acylase 
content of ca. 20%.[48] Processes to synthesize amino acids using immobilized enzymes (as well as whole cells) 
were being commercialized in Japan from 1973.[49] 
 
Scheme 2: Top: Isomerization of D-glucose to D-fructose, catalyzed by an immobilized glucose isomerase as used in the production of HFCS. 
Bottom: Hydrolysis of Penicillin to give 6-APA, which can then be acylated to give several semi-synthetic antibiotics.  
4 The	DNA	revolution	
In order for enzymes to enjoy more widespread use, their production had to be ramped up dramatically. 
In addition, to apply the insights into enzyme mechanisms described above, enzyme active sites had to be 
tweaked somehow. The key to both these problems was the understanding of how DNA encodes proteins, as well 
as the development of efficient ways of manipulating DNA. Of course, in parallel to the research into proteins 
described above, research into DNA was also ongoing.  While DNA was originally viewed as less important than 
proteins (due to its simple make-up of four building blocks), this view quickly changed with the discovery that it 
was the carrier of hereditary information by Avery in 1944.[50] Of course, the correct structure of DNA was 
postulated in 1953 by Watson and Crick[51] (Nobel Prize in Physiology or Medicine in 1962) from X-ray diffraction 
data by Rosalind Franklin.  
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Figure 8: The genetic code. Codons consisting of three bases (triplets) correspond to different amino acids. Each amino acid may be spelled 
by multiple codons (the code is degenerate).  The chart is read from the inside outwards (following the red arrows), e.g. “AUG” corresponds 
to the start codon, methionine, corresponding to the beginning of a protein. The genetic code is universal, i.e. identical across all organisms 
with only a few exceptions. https://commons.wikimedia.org/wiki/File:Aminoacids_table.svg, public domain. 
This quickly led to a postulation of how genetic information is encoded in DNA: the hypothesis that DNA 
encodes amino acid sequences[26e] and that the amino acid sequence alone determines the structure of proteins, 
as demonstrated by Anfinsen in 1961[52] (Nobel Prize in Chemistry in 1972). The process of transcription of DNA 
into mRNA and the translation of mRNA into protein itself was broadly solved within a decade of the discovery of 
the structure of DNA; transcription as a concept was proposed by François Jacob and Jacques Monod in 1961[53] 
(Nobel Prize in Physiology or Medicine in 1965). In the same year, mRNA was discovered,[54] the triplet code was 
established,[55] and the first codon (UUU) was solved by Nirenberg.[56] In competition with several other groups,[57] 
amongst them Gobind Khorana developing a sequence specific chemical synthesis of polynucleotides, the genetic 
code (Figure 8) was fully solved by 1966 and its universality established by 1967[58] (Nirenberg, Khorana and 
Robert W. Holley (for the isolation of tRNA) received the Nobel Prize in Physiology or Medicine in 1968).  
Understanding the meaning of the genetic code of course is of limited use, unless one can also read the 
DNA sequence. Frederick Sanger developed an ingenious hi-jacking of normal DNA replication in 1977 (Figure 
9):[59] by supplying a small quantity of nucleotides that could not be further extended (because they missed the 
3ʹ-OH), strands of DNA truncated after every A (or C, G, or T; depending on which was supplied as the 
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dideoxynucleotide) were produced, which could be separated by size using gel electrophoresis. Repeating this 
experiment for all four nucleotides, the sequence of bases in the template could be deduced. This is earned 
Frederick Sanger his second Noble Prize in Chemistry in 1980. While initially DNA was visualized using radioactive 
labels, this was quickly replaced by using fluorescently labelled dideoxynucleotides, allowing for all four bases to 
be present in the same reaction mixture, increasing throughput. Using capillary electrophoresis, automated 
sequencing became possible.[60] Next-generation sequencing, introduced in the mid-2000s, involves the massive 
parallelized sequencing of many smaller DNA segments that are then assembled in-silico.[61] This has significantly 
reduced the cost and time of genome sequencing, and thus resulted in a dramatic increase of available genomes, 
with over 55000 genomes deposited in the NCBI database, as of August 2020.[62] 
 
Figure 9: Principle of Sanger sequencing: A DNA strand (blue) is copied by DNA polymerase. If a small quantity of dideoxynucleotides 
(ddNTP) is offered in addition to deoxynucleotides (for example ddCTP), chains will terminated whenever a ddCTP is incorporated instead 
of a dCTP, as the 3ʹ-OH needed for chain-extension is missing. If this experiment is repeated for all four nucleotides, and the products are 
separated by size, the sequence of the DNA template can be inferred. Modern Sanger sequencing includes all four ddNTPs in a single 
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sequencing reaction, and distinguishes incorporation of the different bases at the termination site via fluorescent labels, such as the label 
(red) for the ddT—BigDye terminator shown.[60] 
At the same time and leading on from Avery’s experiment, the transmission of genetic information in 
bacteria was being investigated. In 1952, Joshua Lederberg coined the term “plasmid” to describe such 
transmissible DNA and discovered the nature of its transmission (Nobel Prize in Physiology or Medicine in 
1958).[63] Also in 1952, Salvador Luria[64] and Giuseppe Bertani[65] observed that bacteriophages from one strain 
of E. coli have a decreased virulence in another, but upon growth in the second strain would show increased 
virulence for it and a decreased virulence for the original strain, observing the effect of restriction enzymes (so 
called because they restrict the growth of bacteriophage). This effect was then also observed for several other 
bacteria. However, it was only in the early 1960s that the nature of these enzymes as site specific endonucleases, 
and that host bacteria protect their own DNA through modification (methylation), was proposed by Werner 
Arber.[66] Mathew Meselson isolated the first such restriction endonuclease in 1968 (EcoK1).[67] These early 
restriction enzymes recognized a specific sequence but did not cut in a specific location, and are now known as 
type I restriction enzymes. Type II restriction enzymes, cutting DNA in specific locations (Figure 10), were 
discovered by Hamilton Smith in 1970 (HindII and HindIII).[68] In conjunction with gel electrophoresis, this allowed 
the digestion of DNA into fragments of defined size which could then be separated, as shown by Daniel Nathans 
in 1971.[69] Arber, Smith, and Nathans won the Nobel Prize in Physiology or Medicine in 1978.  
 
Figure 10: Type I restriction enzymes cut at a non-defined remote location from the recognition site (example of EcoKI). Type II restriction 
enzymes cut at a well-defined position within (or close to) the recognition sequence, often in a staggered way, producing cohesive ends 
(example of HindIII).  
As many type II restriction enzymes produce palindromic single stranded overhangs, it was then realized 
that DNA from different sources could be stitched together if cut with the same restriction enzyme, through the 
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action of DNA ligase. The first such “recombinant” DNA was reported by Paul Berg in 1972 (Nobel Prize in 
Chemistry in 1980).[70] It thus became possible to introduce any piece of DNA from any organism into (for 
example) E. coli.[71] Thus, plasmids for convenient introduction of such recombinant DNA were being developed 
in the 1970s.[70c] On of the most famous of these plasmids is pBR322, developed by Bolivar and Rodriguez (BR) in 
1977.[70c,72] This plasmid made use of two antibiotic resistance genes and several unique restriction sites within 
them to allow for the selection of colonies that had a) up-taken the plasmid and b) up-taken a plasmid containing 
an insert (Figure 11). The propagation of recombinant DNA in a new host is referred to as cloning. The pUC series 
of plasmids (UC for University of California), derived from pBR322, allowed for colorimetric detection of inserts.[73] 
Finally, the pET series of vectors, also derived from pBR322, was created in the late 1980s and included a T7 
promotor, allowing for the selective expression of the DNA insert (ET for Expression by T7 RNA Polymerase).[74a,b] 
Strains of E. coli were generated containing the gene for the T7 polymerase, under the control of a modified lac 
promoter (lacUV5), as a lysogen of the DE3 phage.[74b-e] Alternative promotor systems were also developed, such 
as the aforementioned lac promoter, as well as the trc promoter, pL promoter, and tetA promoter, and more, 
each with their own advantages and draw-backs.[75]  
 
Figure 11: Left: Map of pBR322, showing the unique restriction sites inside both antibiotic resistance genes. Right: Generic map of a typical 
(empty) expression vector, having an origin of replication (for replication in vivo), a selective marker (Ampicillin resistance in this instance), 
and the  T7 promoter and terminator flanking a His-tag (to allow purification of the insert) and the multiple cloning site, which contains a 
large number of unique restriction sites (not shown) for easy cloning.  
These developments in molecular biology revolutionized enzymology and biocatalysis. For the first time, 
the DNA sequence of an enzyme of interest could be determined and cloned, and the enzyme could be over-
expressed in E. coli (or another suitable organism) and thus be obtained in sufficient quantities to be studied and 
used in industrial applications. The first recombinant protein produced was insulin in 1978, and the commercial 
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production of human insulin started in 1982.[76] Prior to that, insulin had to be isolated from pigs or cows and 
often had limited and inconsistent efficacy, as well as inconsistent supply.[77] DNA recombinant technology also 
allowed penicillin acylase to be obtained in sufficient quantities and enabled its widespread application toward 
the synthesis of 6-APA, as mentioned above.[45e,48] Indeed, penicillin acylase was one of the first enzymes 
expressed recombinantly, in 1979, only one year after insulin.[45d,48] The availability of this enzyme also enabled 
the development of its application in the reverse direction, catalyzing the amide bond formed between 6-APA 
and the side chains found in semi-synthetic antibiotics such as amoxicillin and ampicillin (Scheme 3, also see 
below for a discussion of the role of immobilization).[44,47,78] Around the same time, recombinant chymosin (which 
selectively hydrolyzes casein between residues F105and M106, resulting in the curdling of milk) started replacing 
natural rennet, obtained from calf stomachs, in cheese-making.[79] This provided a cheaper, more stable supply 
for cheesemaking as well as more consistent results due to a higher purity. By 2006, up to 80% of all rennet was 
recombinant chymosin and cheese production in the US had increased over two-fold.[80]  
 
Scheme 3: Application of penicillin acylase for the synthesis of amoxicillin and ampicillin from 6-APA. X = NH2 or OMe.  
5 Directed	evolution	and	the	beginnings	of	modern	biocatalysis	
As great as natural enzymes are at carrying out their function, they often present drawbacks which make 
them unsuitable for industrial applications such as their lack of stability, (co-)solvent-tolerance, or a very limited 
substrate scope. While immobilization can address the stability problems (see below),[81] it quickly became 
desirable to be able to change the properties of the enzymes themselves. Of course, to some extend this had 
already been done routinely, through strain optimization. Whole organisms were subjected to mutation-inducing 
conditions, such as radiation or chemical agents, and the resulting strains were screened for favorable 
phenotypes.[82] Through this method, strains producing larger quantities of desirable products, either specific 
enzymes (such as in the case of penicillin acylase at Bayer mentioned above) or chemicals could be obtained, and 
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entirely new pathways could be introduced.[83] However, these approaches were slow, unlikely to directly change 
the properties of any specific enzyme, and could only really be applied to organisms with sufficiently short 
replication-cycles. However, with the availability of recombinant DNA, as well as the understanding of enzymes 
and their mechanisms as outlined above, introduction of specific mutations into a target enzyme was now within 
reach, irrespective of the organism it originated from. Indeed, a general method for site-directed mutagenesis 
was being reported by Michael Smith in 1978 (Nobel Prize in Chemistry in 1993), the same year as the cloning of 
insulin was achieved. By designing DNA primers, harboring the desired mutations, complimentary to the target 
sequence to be mutated, and extending with DNA polymerase using the target sequence as a template, copies 
containing the mutation could be made (Figure 12).[84] Of course, efficient syntheses of specific DNA sequences 
such as those developed by Khorana,[85] Gillam,[86] and Caruthers[87]  were instrumental for this.[88]  
 
Figure 12: The principles of PCR: DNA is denatured at high temperature, primers supplied in the reaction mixture are annealed, and the 
template is copied. Repeated cycles exponentially amplify the target sequence. Site-directed mutagenesis: a mutation is incorporated in 
the primer; the amplified product now contains the changed base-pair. epPCR: a polymerase that occasionally incorporates incorrect 
nucleotides is used. The product now contains a set of different sequences that differ from the parent in a few positions. Recombination: 
several sequences are shuffled to produce a diverse set of new sequences from the parents.  
Using this approach, the role of catalytic residues could be directly investigated. For example changing the 
cysteine in the catalytic triad found in tyrosyl tRNA synthase to a serine (as found in esterases mentioned above) 
greatly reduces the efficiency of the enzyme.[89] Indeed, the role of several residues in several enzymes could now 
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be quantified, confirming and in some cases revising mechanisms that had been postulated based on 
crystallography.[90a] However, using this technique to introduce desirable properties into enzymes was quickly 
met with the realization that the effect of mutations was often unpredictable, and rational engineering of 
enzymes was often not successful. However, a shift was quickly made toward a more random approach such as 
the use of site-saturation mutagenesis, where targeted residues were changed to all possible amino acids rather 
than a specific one. Through this, some progress was made such as the introduction of a stabilizing mutation into 
subtilisin, a protease with application in laundry detergents,[81,90] or enhanced thermostability of glucose 
isomerase.[91] 
With the development of the polymerase chain reaction (PCR, Figure 12) in the 1980s by Kary Mullis (Nobel 
Prize in Chemistry in 1993), it became possible to produce large numbers of copies of DNA sequences from a 
single template.[92] By modulating the fidelity of the polymerase, random mutations could be introduced into the 
amplified product (error-prone or epPCR, Figure 12). In the early 1990s, Frances Arnold used this technique to 
create large libraries of mutants to which she then applied evolutionary pressure. In her own words,[93] she  
“rejected microbial growth or survival selections favored by microbiologists and geneticists. Thus we turned 
to good old-fashioned analytical chemistry to develop reproducible, reliable screens that reported what 
mattered to us.”  
In doing so she managed to produce a variant of subtilisin E that could tolerate high concentrations of DMF, 
introducing a total of 10 mutations.[94] Thus, the field of directed evolution was born. In 1994, Pim Stemmer 
introduced the concept of DNA shuffling (Figure 12), mimicking DNA recombination which occurs in organisms as 
a way to increase genetic diversity, and applying it to recombinant DNA in vitro. Without being restricted to genes 
from a single species, very diverse proteins could be mixed together to create new sequences very distant from 
natural ones.[95] This technique proved very powerful on its own, but especially when combined with epPCR, 
allowing the combination of mutations from several mutants without the need for any understanding of how the 
different mutations would interact with each other.[96] Frances Arnold received the Nobel Prize in Chemistry in 
2018 for the directed evolution of enzymes. In addition to co-solvent tolerance, directed evolution was quickly 
used to create enzymes with improved thermostability,[97a-d] pH stability,[97c] as well as enhanced activity at low 
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temperatures,[97c,e] activity toward unnatural substrates,[96,98] modified enantioselectivity,[99] or combinations of 
the above. Thus, it quickly established itself as a powerful tool in protein engineering across structurally and 
functionally diverse classes of enzymes. Using random mutagenesis methods it was quickly realized that beneficial 
mutations were often found in unexpected parts of the enzymes, explaining why early rational attempts struggled 
at accomplishing these modifications.[81,93,100]  
 
Figure 13: The 12 principles of green chemistry, reproduced with permission from ACS Green Chemistry Institute® 
(https://www.acs.org/content/acs/en/greenchemistry/principles/12-principles-of-green-chemistry.html). Copyright 2020 American 
Chemical Society. 
The sudden availability of biocatalysts with properties suitable for industrial applications, as well as the 
ability to create those properties at will, made them very attractive for use in synthetic applications that so far 
had been considered out of reach.[101] Of course, catalysis itself had become a major field of interest in synthetic 
chemistry in the second half of the 20th century, as the environmental impact of traditional (stoichiometric) 
chemistry was gaining attention.[102] This gained more traction with the conceptual development of green 
chemistry in the 1990, in parallel to the advances made in biocatalysis outlined above.[103]  Thus, it is not surprising 
that biocatalysis formed a key strategy of accomplishing the goals of green chemistry from the start.[102b] Indeed, 
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it promises to address many of the “12 principles of green chemistry” (Figure 13), in particular with regard to 
hazardous reagents and waste, energy requirements, number of steps, and their inherently renewable and 
biodegradable nature.[104] Indeed, the number of biocatalytic processes in industry started increasing rapidly and 
continues to do so to this day: there were around 60 processes in 1990, 134 processes in 2002, and several 
hundred by 2019.[105] 
Perhaps one of the most successful examples developed at the time was the use of lipases, in particularly 
CalB from Candida antarctica, in organic solvents, allowing ester and amide formation without competing 
hydrolysis, which is frequently employed in (dynamic) kinetic resolutions of chiral alcohols and amines. The latter 
was developed at BASF[106] and is often referred to as the “BASF process” or “ChiPros technology” (Scheme 4).[107]  
By 2004, multiple BASF plants produced chiral amines on a >1000 ton scale per year, and this process is still in use 
today. The reactions can be carried out without solvent, are often nearly quantitative, both amine and amide are 
readily isolated, and the undesired product can be recycled, making this process highly efficient.[108] 
 
Scheme 4: The lipase-catalyzed BASF process for the kinetic resolution of amines. Enantioselectivity is often essentially perfect and 
conversions quantitative, the amide and amine can be separated by distillation, the amide is readily hydrolyzed (giving access to both 
enantiomers), and the undesired enantiomer can be racemized and recycled. The process can also be run neat (e.g. in the case of 1-
methoxy-2-aminopropane).[108b] Other esters than the ethyl may be used; however, the methoxy-group is critical for an efficient reaction. 
6 “Smart”	libraries	and	applications	of	enzyme	engineering		
While the BASF process uses a wild-type enzyme, stabilized through immobilization, a strong interest in 
enzyme engineering has developed in industry. One major barrier to directed evolution is screening. In Frances 
Arnold’s original paper,[94a] the enzyme was secreted from colonies of bacteria and digestion of the substrate in 
plates could be easily observed by a decrease in turbidity, thus allowing the screening of a large number of 
variants relatively easily. However, in general screening is not straightforward and usually it is the bottleneck. 
This is tackled on two fronts: development of faster high-throughput screens, as well as reduction of the size of 
libraries by increasing the proportion of hits. While the former is often highly specific to the (class of) enzymes 
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being evolved, more general concepts exist for the latter.[109] For example, the structure of the enzyme may be 
used to assess which recombinations are more likely not to disrupt the overall fold of the enzyme, in a process 
called SCHEMA,[110] which can then be used to reduce the size of combinatorial libraries. 
Advances in the understanding of protein structures as well as dynamics have increasingly allowed target 
residues to be identified with more reliability than was previously possible, reducing the need for random 
mutagenesis across the whole gene although it remains a valuable tool.[111] This is accomplished using increasingly 
sophisticated bioinformatic tools, to allow for the docking of substrates into active sites, molecular dynamic 
simulations, and protein structure modeling, which can aid to predict the likely effect of potential mutations. One 
very powerful tool that has emerged is Rosetta, which also has been applied for the complete de-novo design of 
proteins.[112] The availability of increasing numbers of structures of diverse enzymes within a given family, and 
the even larger availability of sequences (due to next generation high-throughput sequencing technologies) allow 
points of natural variation to be identified which may then be targeted. The flexibility of residues as determined 
by X-ray crystallography may also help identify target regions.[113] Alternatively, random mutagenesis might be 
used to identify hotspots which are then further investigated by more targeted mutagenesis.[114] In addition, the 
amino acids found in nature for a given position can inform which substitutions to include in a given library.[115]  
Several residues may be targeted together, to increase the chance of detecting synergistic effects of 
mutations. One such approach is combinatorial active site testing (CASTing), developed by Manfred Reetz,[116] 
whereby multiple residues lining the active site are saturated at the same time, allowing for synergistic effects 
between mutations to emerge. This has been particularly successful in changing enantioselectivities and substrate 
scopes of enzymes.[107,117] Amine dehydrogenases (AmDH) were created from amino acid dehydrogenases in this 
way.[118] Several sites of interest (each potentially consisting of multiple residues) may be targeted sequentially, 
in a process call Iterative Saturation Mutagenesis (ISM), also developed by Reetz.[119]  
Statistical tools and machine learning are also a powerful way to increase the efficiency of directed 
evolution,[120] such as the use of protein sequence activity relationships (ProSAR).[121] In an initial library, 
mutations are classified as beneficial, neutral, or detrimental and can inform which mutations to incorporate into 
subsequent libraries, as opposed to taking the best overall variant and generating a new library. This strategy was 
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successfully applied by Codexis in the engineering of a halohydrin dehalogenase (HHDH) for the synthesis of (R)-
4-cyano-3-hydroxybutyrate, a key intermediate for the synthesis of atorvastatin, a cholesterol-lowering drug.[122] 
Overall, the volumetric productivity was improved 4000-fold over 18 rounds of evolution and 35 mutations were 
introduced, meeting the process requirements for the enzyme. The authors note that half of the mutations 
introduced in the final variant were initially not present in the best variant when selected and would have been 
missed in a hit-based approach. While this approach can reduce screening efforts, it requires a larger sequencing 
effort. However, this has become increasingly possible as the cost of DNA sequencing has steadily declined.[81] 
 
 
Figure 14: Evolution of ATA-117 to produce sitagliptin,[123] compared to the chemocatalytic route using a rhodium catalyst. Over 11 rounds 
of evolution, the conditions of the screening (substrate loading, temperature, cosolvent concentration (Rd 3-6 MeOH, otherwise DMSO) 
were gradually increased to the process level. Overlaid is the steady increase in conversion under process conditions, as well as the increase 
in the total number of mutations (note, several mutations changed throughout the process).  
Codexis and Merck combined several of these approaches to engineer a transaminase for the synthesis of 
sitagliptin. Starting from an enzyme with no activity toward the substrate and minimal activity toward a truncated 
analogue, 11 rounds of engineering (Figure 14) led to a catalyst that outcompeted the alternative rhodium-
catalyzed reductive amination process in terms of efficiency, yield, enantioselectivity, and waste formation. 
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Overall, 27 mutations were introduced using a combination of site-saturation mutagenesis, combinatorial 
libraries (including diversity from homologous sequences), proSAR, and epPCR, screening a total of 36480 
variants.[123] Highlighting that, even with the use of tools to maximize the efficiency of evolution, a huge screening 
effort may still be required for significant catalyst improvements. 
In another more recent example, GSK evolved an imine reductase (IRED) to meet the process requirements 
for the synthesis of the LSD1 inhibitor GSK2879552, currently in clinical trials.[124] Screening of their in-house panel 
(of at least 85 IREDS)[125] revealed a suitable candidate for mutagenesis. Given the scarcity of structural data on 
IREDs and that their highly dynamic mechanism is not fully understood, an initial round of site-saturation 
mutagenesis was carried out on 256 out of 296 positions. Beneficial mutations from that round were then used 
to generate combinatorial libraries, which were then analyzed using the proprietary CodeEvolver software from 
Codexis. Statistical analysis was performed to identify pairwise interactions of beneficial mutations which were 
then included in another combinatorial library in a final third round of evolution, yielding an enzyme with 13 
mutations that met or exceeded the process requirements, resulting in improved sustainability metrics over 
previous route (Figure 15). The enzyme was then used to synthesize 1.4 kg of GSK2879552 for use in additional 
rounds of clinical trials.  
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Figure 15: Engineering of an IRED for the synthesis of GSK2879552, and the alternative chemical route. Insert: improvement of the catalyst 
over 3 rounds of evolution; acceptable operating space (black dotted line), wild type IR-46 (grey), M1 (orange), M2 (green), M3 at small 
scale (blue) and process scale (red). Adapted with permission from Springer Nature (ref.[124]), copyright 2019. 
Increasingly, directed evolution has also been applied to create enzymes carrying out reactions not 
observed in nature, by exploiting the promiscuous nature of enzymes (Figure 16). Frances Arnold’s group 
reported on the evolution of a cytochrome c (cyt c), [126] a protein without any catalytic role in nature, to form 
carbon-silicon bonds, a reaction not observed in nature. After screening several P450 enzymes, myoglobins, and 
cyt c variants, they identified a cyt c from Rhodothermus marinus with low levels of catalytic activity for this 
reaction. Iterative site-saturation mutagenesis of just three key residues—an iron coordinating methionine, and 
two additional residues close to the heme group—resulted in a catalyst with a total turnover number (TTN) of 
>1500, a >33-fold improvement over the wild-type (wt) and a >375-fold improvement over free heme, 
outperforming the best chemical catalysts for this reaction. In addition, the turnover frequency (TOF) was 
increased 7-fold, the reaction proceeded with nearly perfect enantioselectivity, and was chemoselective for 
carbene insertion into silanes over alcohols and amines (Figure 16). 
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Figure 16: Top: Exploiting enzyme promiscuity to evolve new catalytic activity. Enzymes often exhibit promiscuous activity toward non-
native substrates or reactions. By applying directed evolution, a “specialist” enzyme might be transformed into another specialist enzyme 
for the new activity, at the cost of diminishing its original function. Such a transformation proceeds through a “low-fitness valley” where 
the enzyme is not very good at either the new or the original function. Figure reproduced with permission from ref.[93] Bottom: This concept 
was applied to evolve a cytochrome c from Rhodothermus marinus (without any native catalytic function) to catalyze Si-H carbene 
insertions.[126] The final variant was 33x more active than the parent and became more specialized for Si-H insertion over N-H insertion 
chemistry, both promiscuous activities of the wt.  
Clearly, in addition to the generation of efficient libraries, the choice of template was key in both examples 
above. Indeed, modern genomics has created huge databases of genes and it has become incredibly easy to 
identify new sequences that likely have a given catalytic function. The dramatic reduction in cost of synthetic 
genes has made it possible to create panels of these sequences, in a way producing a “smart” library of sequences 
already pre-selected by natural evolution. The likely function of a DNA sequence may be determined from 
sequence similarity to other proteins of known function (using search algorithms such as BLAST),[127] as well as 
the identification of motifs.[128] In addition, structure based searches of crystal structures of unknown function 
may yield new biocatalyst.[129] 
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7 Enzyme	immobilization	and	flow	chemistry	
Protein immobilization, which, as already outlined above, is a key strategy for enzyme stabilization and 
reusability, has also become more advanced and a whole plethora of different strategies and supports are 
available (Figure 17). Those are needed in part because protein immobilization can be highly unpredictable, and 
because of application-dependent requirements on the immobilized catalyst (such as particle size, swelling, 
hydrophilicity/hydrophobicity, etc.). Enzyme immobilization may be mechanical or physiochemical, the latter can 
be further divided into covalent or noncovalent/adsorption immobilization. Immobilized proteins may also be 
used in continuous (i.e. flow chemistry) processes, which is particularly attractive for its scalability, improved 
efficiency, and increased control.[130] 
Mechanical immobilization relies on the entrapment of the enzyme in a matrix that restricts its movement 
(Figure 17A). This has the advantage that the enzyme itself is not being modified, while allowing for its 
environment to be fine-tuned. However, mass transfer to and from the enzyme is often impaired.[131] 
Furthermore, leaching of the enzyme can occur.[132] Adsorption onto a solid support is another simple 
immobilization strategy. However, it too often suffers from leaching of the enzyme from the support. It its 
simplest form (hydrophobic, hydrophilic or ionic interactions between support and enzyme. Figure 17B), no 
control over the orientation of the enzyme is achieved and the entrance to the active site may become 
blocked.[133] One of the most widely used biocatalysts, CalB, is immobilized in this way (Novozym 435),  through 
hydrophobic interactions between the enzyme and an acrylic resin support. While leaching is an issue in an 
aqueous environment, this is suppressed in the organic solvents in which it is usually used.[134]  
More specific adsorption is possible with the use of tags. Attached at either the N- or C-terminal of the 
protein, they can help orient the enzyme in a favorable position. Examples include the use of a polyhistidine-tag 
(His-tag, Figure 17C), originally developed for efficient protein purification in 1988,[135] which coordinates to 
transition metal cations, streptavidin with its remarkably high affinity for biotin, and sugar-lectin interactions. 
While a His-tag is encoded genetically, the other two examples require biotinylation or glycosylation, respectively. 
This also allows for enzyme purification and immobilization to be combined into a single step. While these 
interactions are stronger than the simple adsorption described above, low levels of leaching can still occur and 
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pose problems for applications in flow, where any enzyme leaching from the column will be lost (as opposed to 
batch processes where temporarily detached enzyme remains in the vicinity of the support and can, in principle, 
reattach). One example are EziG beads, made of controlled porosity glass which has been modified to coordinate 
to metal ions.[136a] They appear to be predominantly used in organic solvents,[136] which appear to suppress 
leaching although use in an aqueous environment without leaching has also been reported (using Fe3+ as the 
cation).[137] 
 
Figure 17: Examples of enzyme immobilization strategies. A) Mechanical entrapment restricts the diffusion of the enzyme. B) Adsorption 
through ionic interactions, offering little control over the orientation of the enzyme. C) Adsorption though affinity, in this case His-tag-
metal coordination, allowing control of over the orientation of the enzyme through the tag placement. D) Covalent attachment, offering 
little control over the orientation of the enzyme. Multipoint attachment can lead to irreversible deformation of the enzyme shape. 
Common functional groups for covalent attachment are carboxylic acids, aldehydes, and epoxides—using amide formation, reductive 
amination, and ring opening, respectively. E) Affinity-directed covalent immobilization orients the enzyme prior to covalent attachment. 
F) By fusing a (small) protein to the enzyme, covalent immobilization and any shape disruption can be localized to that fusion protein, 
reducing the effect on the enzyme. However, such an enzyme is more exposed to the environment and stability benefits from 
immobilization may be diminished. Not shown are covalent crosslinking of enzymes (e.g. using a dialdehyde), and the inherent different 
properties of supports, with respect to e.g. their size, pore-size, hydrophilicity/hydrophobicity, etc. 
The problem of leaching can be fully avoided using covalent immobilization (Figure 17D). However, it often 
results in severe distortions of the enzyme and loss of activity, although this is highly dependent on the enzyme 
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and support and often unpredictable. Leaching may also still occur for multimeric proteins if not all subunits are 
covalently attached. Moreover, once the enzyme has degraded the support cannot be reused whereas with 
adsorption the enzyme may be desorbed and replaced with fresh enzyme.[134] The orientation of the enzyme may 
be controlled by initially adsorbing the enzyme onto the support using tags, followed by the formation of the 
covalent attachment (Figure 17E). The distortion of the enzyme can be alleviated using small protein tags, with 
the covalent attachment points being on that protein rather than the enzyme itself (Figure 17F).[138] However, as 
the enzyme is more exposed to solvent, the stabilizing effect of immobilization is reduced. One elegant tag 
directed covalent immobilization is the use of the SpyTag/SpyCatcher system, a peptide and protein that 
spontaneously form an isopeptide bond when coming together.[139]   
 
Scheme 5: Competing acyl transfer (red) and hydrolysis reactions (blue) catalyzed by Penicillin acylase. By tuning the characteristics of the 
support, synthesis can be kinetically favored over the thermodynamically favored hydrolysis reaction. 
Enzymes may also be covalently cross-linked into cross-linked enzyme aggregates (CLEAs), an 
immobilization without a support. However, the poorly defined properties (such as particle size) of these 
aggregates often render them unsuitable for flow applications. However, adsorption of these aggregates onto a 
support with more defined properties can alleviate this issue. Glucose isomerase, immobilized in this way, is being 
used for the production of HFCSs in flow on a 10 million tons per year scale, using 500 tons of the immobilized 
catalyst.[45f,108b,140] Regardless of the immobilization technique used, tuning the characteristics of the support with 
respect to e.g. their size, pore-size, hydrophilicity/hydrophobicity, etc. is also key. For example, tuning the 
composition of the support reduced the synthesis/hydrolysis (S/H) ratio of covalently immobilized penicillin 
acylase (Scheme 5). This was a key step in rendering it suitable for the kinetically controlled synthesis of various 
semi-synthetic β-lactam antibiotics.[44,47,78]  
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In some cases, subunit dissociation followed by leaching can significantly reduce the operational stability 
of covalently immobilized biocatalysts. In those cases, coating the biocatalysts either before or after 
immobilization with other polymers, such as polyethylenimine (PEI) or activated dextran can help maintain the 
quaternary structure.[131] However, as with any immobilization, excessive rigidification of the enzyme can result 
in a loss of catalytic efficiency if structural rearrangements necessary for catalysis are impeded. In addition, the 
increased complexity of more sophisticated immobilization techniques often outweighs any benefits bestowed 
on the catalyst. In general, the simplest catalysts that can meet the process requirements is the preferred one. 
Synthetic cascades, without the need for purification of intermediates are very attractive due to the 
reduced amount of waste that is produced. In addition, intermediates that are too unstable to be isolated may 
be telescoped to the next step, offering alternative routes to classical synthesis. Flow chemistry, being inherently 
modular by design, is a very important platform for such cascades. Sequential reactions can be 
compartmentalized, avoiding incompatibility between reagents as well as allowing the conditions to be fine-
tuned for each reaction.[130] Cascades involving biocatalysis may either be multiple enzymatic reactions combined 
in sequence, or chemo(catalytic) reactions combined with enzymatic reactions.[141]  
A nice example of the former was demonstrated by Contente and Paradisi,[142] who developed a cascade in 
flow converting amines into alcohols, employing a transaminase and either an alcohol dehydrogenase (ADH) or 
ketoreductase (KRED) that had been immobilized covalently on epoxide functionalized methacrylate beads 
(Scheme 6A). By compartmentalizing both catalysts, reaction temperatures and times were optimized 
independently for each step. In addition, in-line purification steps allowed the removal of product. Recycling of 
the aqueous phase containing co-factors and buffer salts was also demonstrated, reducing the overall amount of 
the cofactors required (from 1:100 to 1:2000) while also eliminating the aqueous waste stream. Uwe 
Bornscheuer’s group demonstrated a Suzuki-Miyaura coupling in batch to produce a biaryl ketone substrate for 
a subsequent transaminase-catalyzed amination in flow (Scheme 6B).[143] Here, the ability of the transaminase 
reaction to tolerate 30% (v/v) DMF as well as salts and palladium from the first reaction step was key. 
Compatibility between palladium and enzyme catalysts can be a problem, as was the case for a halogenase-
Suzuki-coupling cascade in batch reported by Latham et al (Scheme 6C).[144] Using free enzyme, ultrafiltration or 
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compartmentalization with a semi-permeable membrane had to be used to physically separate the enzyme and 
Pd catalyst. Alternatively, immobilization of the halogenase into CLEAs was also successful. 
  
Scheme 6: Three examples of enzymatic cascades. A) Transformation of amines into alcohols, using an immobilized transaminase and 
either an ADH or KRED in flow.[142] B) A Suzuki cross-coupling to produce a bi-aryl ketone which is then aminated using a transaminase 
catalyst. The transaminase had to tolerate 30% DMF carried over from the cross-coupling, as well Pd catalyst, excess base, and unreacted 
boronic acid.[143] C) halogenation of aromatic compounds using a halogenase, followed by a Suzuki coupling. The enzyme had to be 
separated, either by ultrafiltration, immobilization, or compartmentalization from the Pd catalyst.[144] 
In another collaboration between Codexis and Merck, a three-step, nine-enzyme cascade to synthesize the 
HIV drug islatravir was developed (Figure 18).[145] This involved engineering of five enzymes to accept unnatural 
substrates, as well as enzyme immobilization to simplify the final purification. For this, a cost-effective affinity 
immobilization using a His-tag was chosen for the first two steps, while the last step used free enzymes. Enzymes 
from seven organisms were used, and each step involved enzymes from either two or three organisms and one 
or three evolved enzymes. Thus, by bringing together the right enzymes from the right organisms (a testament 
to the vast number of genome sequences that are available) and applying directed evolution only were needed, 
the number of steps in the synthesis of islatravir was cut more than in half (from 12-18 steps), and the overall 
yield was almost doubled (51% vs 37% previously reported[146]). Atom economy was improved, overall waste was 
reduced, and hazardous reagents (such as a Birch reduction in Fukuyama et al.’s synthesis[146]) were avoided.  
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Figure 18: Nine-enzyme cascade to produce the HIV drug islatravir. Five enzymes had to be evolved. Compared to a chemical synthesis, 
steps were reduced by more than half and yield was almost doubled. No purification of intermediates was necessary. Immobilized enzymes 
shown attached to spheres. Figure adapted from Huffman et al.[145] with permission from AAAS. 
8 Summary	and	Outlook	
Through the elucidation of enzymatic mechanisms and enzyme structures, as well as the development of 
powerful tools for DNA manipulation, engineered enzymes are being applied in increasingly complex syntheses. 
However, challenges remain. Enzyme engineering is time consuming and while excellent enzyme variants have 
been created, it is not always successful. Even though significant advances have been made in the understanding 
of protein folding and predicting the effects of mutations, we still rely on the principles of directed evolution 
developed by Frances Arnold. Further research into the properties of enzymes is necessary to increase their 
predictability, which will lead to a future where enzymes can be applied more routinely.  
Promising approaches include the use of increasingly sophisticated machine learning, based on large sets 
of sequences of known function (either wild-type sequences or mutants).[120, 147] Exploring a large sequence space 
has become increasingly possible due to the advances in gene synthesis, building on DNA synthetic strategies and 
improvements in DNA sequencing mentioned earlier.[148] Understanding the trajectories of substrates in addition 
to their interactions once inside the active site (the aim of traditional substrate docking) allows new target 
residues to be identified.[149] Additionally, the de-novo design of proteins has offered a window into entirely new 
protein sequences unknown in nature. In addition to offering exciting new catalysts, this is also an invaluable way 
of testing our understanding of protein folding and the factors that influence catalytic efficiency.[150] Expanding 
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the genetic code to include unnatural amino acids with functional groups not found in nature may further increase 
enzyme performance and open up new reactions currently outside of the scope of biocatalysis.[151] Synthetic 
biology, which focusses on the introduction of new metabolic pathways into organisms to produce valuable 
chemicals from cheap and renewable starting materials, is another exciting emerging field.[152] 
More fundamental challenges also remain, such as protein expression which is often difficult to predict. 
While E. coli has been undoubtedly the expression organism of choice, due to the vast number of molecular 
biology tools available and the ease with which it can be grown, some proteins cannot be expressed at high levels 
or in soluble form and, recently, concerns about low levels of endotoxins that are sufficient to cause an immune 
response have been raised.[153] Thus, alternative expression systems are needed such as fungi and extremophilic 
archaea to allow for the expression of proteins incompatible with E. coli and bypass potential toxicity.[154] 
Lastly, it is still extremely challenging to bring a biocatalytic process to market. Often, even heavily 
engineered enzymes fall short in terms of space-time-yield compared to the best heterogeneous catalysts 
(particularly challenging for bulk chemicals). Additionally, a significant investment of both time and money is 
necessary to develop a biocatalytic process. This is especially true for synthetic biology, e.g. in the case of the 
anti-malarial drug artemisinin which required 10 years of research and >$150 million to engineer an organism 
that could produce it.[155] Clearly, additional research to address these issues is needed and a closer interaction 
between academia and industry could further speed up the process. Nonetheless, the many examples of 
successful biocatalytic processes mentioned in this review (as well as many not mentioned) highlight the power 
of enzymes and the bright future of the field of biocatalysis.    
Acknowledgments		
This work was supported by the Biotechnology and Biological Sciences Research Council through the iCASE 
scheme in collaboration with Johnson Matthey [grant number BB/M008770/1]. 
Keywords: enzymes • protein engineering • history of biocatalysis • immobilization • green chemistry 
 
[1] P. E. McGovern, J. Zhang, J. Tang, Z. Zhang, G. R. Hall, R. A. Moreau, A. Nuñez, E. D. Butrym, M. P. Richards, C. S. Wang, G. Cheng, 
Z. Zhao, C. Wang, Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 17593–17598. 
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
35 
 
[2] E. F. Armstrong, Nature 1933, 131, 535–537. 
[3] E. Büchner, “Eduard Büchner – Nobel Lecture: Cell-free fermentation,” can be found under 
https://www.nobelprize.org/prizes/chemistry/1907/buchner/lecture/, 1907. 
[4] W. Kühne, in Verhandlungen Des Naturhistorisch-Medicinischen Vereins Zu Heidelb., 1877, pp. 190–193. 
[5] A. J. B. Robertson, Platinum Met. Rev. 1975, 19, 64–69. 
[6] J. H. Northrop, “John H. Northrop – Nobel Lecture: The preparation of pure enzymes and virus proteins,” can be found under 
https://www.nobelprize.org/prizes/chemistry/1946/northrop/lecture/, 1946. 
[7] K. L. Manchester, Trends Biotechnol. 1995, 13, 511–515. 
[8] a) R. Kohler, J. Hist. Biol. 1971, 4, 35–61; b) G. E. Hein, J. Chem. Educ. 1961, 38, 614–619. 
[9] J. B. . Sumner, “James B. Sumner – Nobel Lecture: The chemical nature of enzymes,” can be found under 
https://www.nobelprize.org/prizes/chemistry/1946/sumner/lecture/, 1946. 
[10] a) H. W. Von Loesecke, Chem. Eng. News 1945, 23, 1952–1959; b) H. Tauber, The Chemistry and Technology of Enzymes, Wiley, 
New York, 1949. 
[11] G. Hildebrandt, W. Klavehn, Manufacture of Laevo-1-Phenyl-2-Methylaminopropanol-1, 1934, US1956950A. 
[12] K. A. N. Maroney, P. N. Culshaw, U. D. Wermuth, S. L. Cresswell, Forensic Sci. Int. 2014, 235, 52–61. 
[13] D. H. Peterson, H. C. Murray, J. Am. Chem. Soc. 1952, 74, 1871–1872. 
[14] M. Breuer, M. Pohl, B. Hauer, B. Lingen, Anal. Bioanal. Chem. 2002, 374, 1069–1073. 
[15] E. Fischer, Ber. Dtsch. Chem. Ges. 1894, 27, 2985–2993. 
[16] K. A. Johnson, R. S. Goody, Biochemistry 2011, 50, 8264–8269. 
[17] A. S. Bommarius, Annu. Rev. Chem. Biomol. Eng. 2015, 6, 319–345. 
[18] L. Pauling, Nature 1948, 161, 707–709. 
[19] H. Eyeing, Chem. Rev. 1935, 17, 65–77. 
[20] a) D. E. Koshland, Proc. Natl. Acad. Sci. U. S. A. 1958, 44, 98–104; b) D. E. Koshland, J. Cell. Comp. Physiol. 1959, 54, 245–258. 
[21] E. Fischer, Berichte der Dtsch. Chem. Gesellschaft 1907, 40, 1754–1767. 
[22] J. S. Fruton, Ann. N.Y. Acad. Sci. 1979, 325, 1–20. 
[23] a) F. Sanger, H. Tuppy, Biochem. J 1951, 49, 463–481; b) F. Sanger, H. Tuppy, Biochem. J 1951, 49, 481–490. 
[24] a) L. Pauling, R. B. Corey, J. Am. Chem. Soc. 1950, 72, 5349; b) L. Pauling, R. B. Corey, Proc. Natl. Acad. Sci. U. S. A. 1951, 37, 729–
740; c) L. Pauling, “Linus Pauling – Nobel Lecture: Modern structural chemistry,” can be found under 
https://www.nobelprize.org/prizes/chemistry/1954/pauling/lecture/, 1954; d) L. Pauling, R. B. Corey, H. R. Branson, Proc. Natl. 
Acad. Sci. U. S. A. 1951, 37, 205–211. 
[25] M. F. Perutz, Nature 1951, 167, 1053–1054. 
[26] a) J. C. Kendrew, G. Bodo, H. M. Dintzis, R. G. Parrish, H. Wyckoff, D. C. Phillips, Nature 1958, 181, 662–666; b) J. C. Kendrew, R. E. 
Dickerson, B. E. Strandberg, R. G. Hart, D. R. Davies, D. C. Phillips, V. C. Shore, Nature 1960, 185, 422–427; c) M. F. Perutz, M. G. 
Rossmann, A. F. Cullis, H. Muirhead, G. Will, A. C. T. North, Nature 1960, 185, 416–422; d) M. F. Perutz, Science 1963, 140, 863–
870; e) J. C. Kendrew, Science 1963, 139, 1259–1266. 
[27] a) S. de Chadarevian, Protein Sci. 2018, 27, 1136–1143; b) Sir Lawrence Bragg, Rep. Prog. Phys. 1965, 28, 1–14. 
[28] M. Jaskolski, Z. Dauter, A. Wlodawer, FEBS J. 2014, 281, 3985–4009. 
[29] a) C. C. F. Blake, D. F. Koenig, G. A. Mair, A. C. T. North, D. C. Phillips, V. R. Sarma, Nature 1965, 206, 757–761; b) L. N. Johnson, D. 
C. Phillips, Nature 1965, 206, 761–763. 
[30] G. N. Reeke, J. A. Hartsuck, M. L. Ludwig, F. A. Quiocho, T. A. Steitz, W. N. Lipscomb, Proc. Natl. Acad. Sci. U. S. A. 1967, 58, 2220–
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
36 
 
2226. 
[31] a) B. W. Matthews, P. B. Sigler, R. Henderson, D. M. Blow, Nature 1967, 214, 652–656; b) D. M. Blow, J. J. Birktoft, B. S. Hartley, 
Nature 1969, 221, 337–340; c) R. Henderson, J. Mol. Biol. 1970, 54, 341–354; d) D. M. Blow, Acc. Chem. Res. 1976, 9, 145–152. 
[32] “PDB Statistics: Overall Growth of Released Structures Per Year,” can be found under https://www.rcsb.org/stats/growth/growth-
released-structures, n.d. 
[33] a) T. D. H. Bugg, Nat. Prod. Reports 2001, 18, 465–493; b) F. H. Westheimer, Adv. Phys. Org. Chem. 1985, 21, 1–35. 
[34] O. Warburg, W. Christian, Helv. Chim. Acta 1936, 19, E79–E88. 
[35] R. R. Williams, J. K. Cline, J. Am. Chem. Soc. 1936, 58, 1504–1505. 
[36] a) E. E. Snell, B. M. Guirard, R. J. Williams, J. Biol. Chem. 1942, 143, 519–531; b) E. E. Snell, J. Am. Chem. Soc. 1944, 66, 2082–2088; 
c) S. A. Harris, D. Heyl, K. Folkers, J. Am. Chem. Soc. 1944, 66, 2088–2092; d) A. E. Braunstein, M. G. Kritzmann, Nature 1946, 158, 
102–103; e) A. E. Braunstein, M. G. Kritzmann, Nature 1937, 140, 503–504. 
[37] a) L. J. Haynes, A. R. Todd, J. Chem. Soc. 1950, 303–308; b) L. J. Haykes, N. A. Hughes, G. W. Kenner, A. Todd, J. Chem. Soc. 1957, 
3727–3732; c) N. A. Hughes, G. W. Kenner, A. Todd, J. Chem. Soc. 1957, 3733–3738. 
[38] a) J. Baddiley, A. R. Todd, J. Chem. Soc. 1947, 648–651; b) J. Baddiley, A. M. Michelson, A. R. Todd, J. Chem. Soc. 1949, 582–586. 
[39] a) S. M. H. Christie, G. W. Kenner, A. R. Todd, Nature 1952, 170, 924; b) S. M. H. Christie, G. W. Kenner, A. R. Todd, J. Chem. Soc. 
1954, 46–52. 
[40] a) D. C. Hodgkin, J. Pickworth, J. H. Robertson, K. N. Trueblood, R. J. Prosen, J. G. White, Nature 1955, 176, 325–328; b) D. C. 
Hodgkin, J. Kamper, M. Mackay, J. Pickworth, K. N. Trueblood, J. G. White, Nature 1956, 178, 64–66. 
[41] a) F. A. Loewus, F. H. Westheimer, B. Vennesland, J. Am. Chem. Soc. 1953, 75, 5018–5023; b) F. H. Westheimer, H. F. Fisher, E. E. 
Conn, B. Vennesland, J. Am. Chem. Soc. 1951, 73, 2403. 
[42] a) R. Breslow, J. Am. Chem. Soc. 1957, 79, 1762–1763; b) R. Breslow, J. Am. Chem. Soc. 1958, 80, 3719–3726. 
[43] a) E. E. Snell, J. Am. Chem. Soc. 1945, 67, 194–197; b) D. E. Metzler, M. Ikawa, E. E. Snell, J. Am. Chem. Soc. 1954, 76, 648–652; c) 
E. E. Snell, J. Biol. Chem. 1944, 154, 313–314. 
[44] A. Bruggink, Synthesis of β-Lactam Antibiotics, 2001. 
[45] a) N. Grubhofer, L. Schleith, Naturwissenschaften 1953, 40, 508; b) F. Michee, E. Dinkloh, Chem. Ber. 1951, 84, 210–212; c) G. 
Manecke, S. Singer, K.-E. Gillert, Naturwissenschaften 1958, 45, 440–441; d) U. T. Bornscheuer, K. Buchholz, Eng. Life Sci. 2005, 5, 
309–323; e) R. P. Elander, Appl. Microbiol. Biotechnol. 2003, 61, 385–392; f) R. A. Messing, A. M. Filbert, J. Agric. Food. Chem. 
1975, 23, 920–923. 
[46] M. L. Hanover, J. S. White, Am. J. Clin. Nutr. 1993, 58, 724S-732S. 
[47] A. Bruggink, E. C. Roos, E. De Vroom, Org. Process Res. Dev. 1998, 2, 128–133. 
[48] K. Buchholz, Appl Microbiol Biotechnol 2016, 100, 3825–3839. 
[49] H. Y. Hsiao, J. F. Walter, D. M. Anderson, B. K. Hamilton, Biotechnol. Genet. Eng. Rev. 1988, 6, 179–219. 
[50] H. Dawes, Curr. Biol. 2004, 14, R605–R607. 
[51] J. D. Watson, F. H. C. Crick, Nature 1953, 171, 737–738. 
[52] C. B. Anfinsen, E. Haber, Sela, F. H. White, Proc. Natl. Acad. Sci. U. S. A. 1961, 47, 1309–1314. 
[53] F. Jacob, J. Monod, J. Mol. Biol. 1961, 3, 318–356. 
[54] a) F. Gros, H. Hiatt, W. Gilbert, C. G. Kurland, R. W. Risebrough, J. D. Watson, Nature 1961, 190, 581–585; b) S. Brenner, F. Jacob, 
M. Meselson, Nature 1961, 190, 576–581. 
[55] F. H. C. Crick, L. Barnett, S. Brenner, R. J. Watts-Tobin, Nature 1961, 192, 1227–1232. 
[56] M. W. Nirenberg, J. H. Matthaei, Proc. Natl. Acad. Sci. U. S. A. 1961, 47, 1588–1602. 
[57] a) M. W. Nirenberg, J. H. Matthaei, O. W. Jones, Proc. Natl. Acad. Sci. U. S. A. 1962, 48, 104–109; b) P. Leder, M. Nirenberg, Proc. 
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
37 
 
Natl. Acad. Sci. U. S. A. 1964, 52, 420–427; c) P. Lengyel, J. F. Speyer, S. Ochoa, Proc. Natl. Acad. Sci. U. S. A. 1961, 47, 1936–1942; 
d) J. F. Speyer, P. Lengyel, C. Basilio, S. Ochoa, Proc. Natl. Acad. Sci. U. S. A. 1962, 48, 63–68; e) D. Söll, E. Ohtsuka, D. S. Jones, R. 
Lohrmann, H. Hayatsu, S. Nishimura, H. G. Khorana, Proc. Natl. Acad. Sci. U. S. A. 1965, 54, 1378–1385; f) M. Nirenberg, Trends 
Biochem. Sci 2004, 29, 46–54. 
[58] R. E. Marshall, C. T. Caskey, M. Nirenberg, Science 1967, 155, 820–826. 
[59] F. Sanger, S. Nicklen,  A. R. Coulson, Proc. Natl. Acad. Sci. U. S. A. 1977, 74, 5463–5467. 
[60] a) B. Rosenblum, L. G. Lee, S. L. Spurgeon, S. H. Khan, S. M. Menchen, C. R. Heiner, S. M. Che, Nucleic Acids Res. 1997, 25, 4500–
4504; b) L. G. Lee, S. L. Spurgeon, C. R. Heiner, S. C. Benson, B. B. Rosenblum, S. M. Menchen, R. J. Graham, A. Constantinescu, K. 
G. Upadhya, J. M. Cassel, Nucleic Acids Res. 1997, 25, 2816–2822. 
[61] S. Goodwin, J. D. McPherson, W. R. McCombie, Nat. Rev. Genet. 2016, 17, 333–351. 
[62] “Genome Information by Organism,” can be found under https://www.ncbi.nlm.nih.gov/genome/browse#!/overview/, n. d. 
[63] a) J. Lederberg, Plasmid 1998, 39, 1–9; b) J. Lederberg, Physiol. Rev. 1952, 32, 403–430. 
[64] S. E. Luria, M. L. Human, J. Bacteriol. 1952, 64, 557–569. 
[65] G. Bertani, J. J. Weigle, J. Bacteriol. 1953, 65, 113–121. 
[66] a) W. Arber, Annu. Rev. Microbiol. 1965, 19, 365–378; b) S. Linn, W. Arber, Proc. Natl. Acad. Sci. U. S. A. 1968, 59, 1300–1306; c) 
W. Arber, S. Lin, Annu. Rev. Biochem 1969, 38, 467–500. 
[67] a) M. Meselson, R. Yuan, Nature 1968, 217, 1110-1114; b) D. Nathans, H. O. Smith, Annu. Rev. Biochem 1975, 44, 273–293. 
[68] a) H. O. Smith, K. W. Welcox, J. Mol. Biol. 1970, 51, 379–391; b) T. J. Kelly, H. O. Smith, J. Mol. Biol. 1970, 51, 393–409. 
[69] a) R. J. Roberts, Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 5905–5908; b) K. Danna, D. Nathans, Proc. Natl. Acad. Sci. U. S. A. 1971, 
68, 2913–2917. 
[70] a) J. E. Mertz, R. W. Davis, Proc. Natl. Acad. Sci. U. S. A. 1972, 69, 3370–3374; b) D. A. Jackson, R. H. Symons, P. Berg, Proc. Natl. 
Acad. Sci. U. S. A. 1972, 69, 2904–2909; c) T. A. Brown, Gene Cloning and DNA Analysis: An Introduction, John Wiley & Sons Ltd, 
2016; d) P. E. Lobban, A. D. Kaiser, J. Mol. Biol. 1973, 78, 453–471. 
[71] S. N. Cohen, A. C. Chang, H. W. Boyer, R. B. Helling, Proc. Natl. Acad. Sci. U. S. A. 1973, 70, 3240–3244. 
[72] a) F. Bolivar, R. L. Rodriguez, M. C. Betlach, H. W. Boyer, Gene 1977, 2, 75–93; b) F. Bolivar, R. L. Rodrguez, P. J. Greene, M. C. 
Betlach, H. L. Heyneker, H. W. Boyer, Gene 1977, 2, 95–113. 
[73] a) J. Vieira, J. Messing, Gene 1982, 19, 259–268; b) C. Yanisch-Perron, J. Vieira, J. Messing, Gene 1985, 33, 103–119. 
[74] a) A. H. Rosenberg, B. N. Lade, D. S. Chui, S. W. Lin, J. J. Dunn, F. W. Studier, Gene 1987, 56, 125–135; b) F. W. Studier, A. H. 
Rosenberg, J. J. Dunn, J. W. Dubendorff, Methods Enzymol. 1990, 185, 60–89; c) F. W. Studier, B. A. Moffattf, J. Mol. Biol. 1986, 
189, 113–130; d) R. Novy, B. Morris, Innovations 2001, 13, 13–15; e) P. Daegelen, F. W. Studier, R. E. Lenski, S. Cure, J. F. Kim, J. 
Mol. Biol. 2009, 394, 634–643. 
[75] a) K. Terpe, Appl. Microbiol. Biotechnol. 2006, 72, 211–222; b) G. L. Rosano, E. A. Ceccarelli, Front. Microbiol. 2014, 5, 172. 
[76] I. S. Johnson, Science 1983, 219, 632–637. 
[77] A. M. Gualandi-Signorini, G. Giorgi, Eur. Rev. Med. Pharmacol. Sci. 2001, 5, 73–83. 
[78] S. R. Marsden, L. Mestrom, D. G. G. McMillan, U. Hanefeld, ChemCatChem 2020, 12, 426–437. 
[79] a) T. J. R. Harris, P. A. Lowe, A. Lyons, P. G. Thomas, M. A. W. Eaton, T. A. Millican, T. P. Patel, C. C. Bose, N. H. Carey, M. T. Doel, 
Nucleic Acids Res. 1982, 10, 2177–2187; b) J. S. Emtage, S. Angal, M. T. Doel, T. J. Harris, B. Jenkins, G. Lilley, P. A. Lowe, Proc. Natl. 
Acad. Sci. U. S. A. 1983, 80, 3671–3675; c) C. L. Hicks, J. O’Leary, J. Bucy, J. Dairy Sci. 1988, 71, 1127–1131; d) A. Kumar, S. Grover, 
J. Sharma, V. K. Batish, Crit. Rev. Biotechnol. 2010, 30, 243–58; e)  G. L. Gilliland, E. L. Winborne, J. Nachman, A. Wlodawer, Proteins 
Struct. Funct. Bioinforma. 1990, 8, 82–101. 
[80] M. E. Johnson, J. A. Lucey, J. Dairy Sci. 2006, 89, 1174–1178. 
[81] U. T. Bornscheuer, G. W. Huisman, R. J. Kazlauskas, S. Lutz, J. C. Moore, K. Robins, Nature 2012, 485, 185–194. 
[82] a) E. A. Carlson, Mutat. Res. - Rev. Mutat. Res. 2013, 752, 1–5; b) E. M. Witkin, Bacteriol. Rev. 1976, 40, 869–907; c) H. J. Muller, 
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
38 
 
Science 1927, 66, 84–87; d) J. F. Crow, S. Abrahamson, Genetics 1997, 147, 1491–1496; e) J. Lederberg, E. M. Lederberg, J. 
Bacteriol. 1952, 63, 399–406. 
[83] a) J. L. Adrio, A. L. Demain, FEMS Microbiol. Rev. 2006, 30, 187–214; b) S. A. Lerner, T. T. Wu, E. C. C. Lin, Science 1964, 146, 1313–
1315; c) S. Parekh, V. A. Vinci, R. J. Strobel, Appl. Microbiol. Biotechnol. 2000, 54, 287–301. 
[84] C. A. Hutchison, S. Phillips, M. H. Edgell, S. Gillam, P. Jahnke, M. Smith, J. Biol. Chem. 1978, 253, 6551–6560. 
[85] H. G. Khorana, Pure Appl. Chem. 1968, 17, 349–382. 
[86] S. Gillam, F. Rottman, P. Jahnke, M. Smith, Proc. Natl. Acad. Sci. U. S. A. 1977, 74, 96–100. 
[87] M. D. Matteucci, M. H. Caruthers, J. Am. Chem. Soc. 1981, 103, 3185–3191. 
[88] S. L. Beaucage, R. P. Iyer, Tetrahedron 1992, 48, 2223–2311. 
[89] G. Winter, A. R. Fersht, A. J. Wilkinson, M. Zoller, M. Smith, Nature 1982, 299, 756–758. 
[90] a) J. A. Brannigan, A. J. Wilkinson, Nat. Rev. Mol. cell Biol. 2002, 3, 964–70; b) D. A. Estell, T. P. Graycar, J. A. Wells, J. Biol. Chem. 
1985, 260, 6518–6521. 
[91] W. J. Quax, N. T. Mrabet, R. G. M. Luiten, P. W. Schuurhuizen, P. Stanssens, I. Lasters, Bio/Technology 1991, 9, 738–742. 
[92] a) J. M. S. Bartlett, D. Stirling, Eds. , Methods in Molecular Biology: PCR Protocols, Humana Press Inc., Totowa, 2003; b) R. K. Saiki, 
S. Scharf, F. Faloona, K. B. Mullis, G. T. Horn, H. A. Erlich, N. Arnheim, Science 1985, 230, 6–11; c) R. K. Saik, D. H. Gelfand, S. Stoffel, 
S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, H. A. Erlich, Science 1988, 239, 487–491. 
[93] F. H. Arnold, Angew. Chemie - Int. Ed. 2019, 58, 14420–14426. 
[94] a) K. Chen, F. H. Arnold, Bio/Technology 1991, 9, 1073–1077; b) K. Chen, F. H. Arnold, Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 5618–
5622. 
[95] a) W. P. C. Stemmer, Nature 1994, 370, 389–391; b) W. P. C. Stemmer, Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 10747–10751. 
[96] J. C. Moore, F. H. Arnold, Nat. Biotechnol. 1996, 14, 458–467. 
[97] a) J. R. Cherry, M. H. Lamsa, P. Schneider, J. Vind, A. Svendsen, A. Jones, A. H. Pedersen, Nat. Biotechnol. 1999, 17, 379–384; b) H. 
Zhao, L. Giver, Z. Shao, J. A. Affholter, F. H. Arnold, Nat. Biotechnol. 1998, 16, 258–261; c) J. E. Ness, M. Welch, L. Giver, M. Bueno, 
J. R. Cherry, T. V. Borchert, W. P. C. Stemmer, J. Minshull, Nat. Biotechnol. 1999, 17, 893–896; d) L. Giver, A. Gershenson, P. O. 
Freskgard, F. H. Arnold, Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 12809–12813; e) S. Taguchi, A. Ozaki, H. Momose, Appl. Environ. 
Microbiol. 1998, 64, 492–495. 
[98] a) T. Kumamaru, H. Suenaga, M. Mitsuoka, T. Watanabe, K. Furukawa, Nat. Biotechnol. 1998, 16, 663–666; b) T. Yano, S. Oue, H. 
Kagamiyama, Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 5511–5515. 
[99] a) O. May, P. T. Nguyen, F. H. Arnold, Nat. Biotechnol. 2000, 18, 317–320; b) K. Liebeton, A. Zonta, K. Schimossek, M. Nardini, D. 
Lang, B. W. Dijkstra, M. T. Reetz, K. E. Jaeger, Chem. Biol. 2000, 7, 709–718. 
[100] a) F. H. Arnold, Acc. Chem. Res. 1998, 31, 125–131; b) F. H. Arnold, A. A. Volkov, Curr. Opin. Chem. Biol. 1999, 3, 54–59; c) M. T. 
Reetz, K.-E. Jaeger, Top. Curr. Chem. 1999, 200, 31–57; d) F. H. Arnold, Nature 2001, 409, 253–257; e) R. E. Cobb, R. Chao, H. Zhao, 
AlChE J. 2013, 59, 1432–1440. 
[101] a) A. Schmid, J. S. Dordick, B. Hauer, A. Kiener, M. Wubbolts, B. Witholt, Nature 2001, 409, 258–268; b) H. E. Schoemaker, D. L. 
Mink, M. G. WubboLts, Science 2003, 299, 1694–1697. 
[102] a) M. A. Murphy, Found. Chem. 2018, 20, 121–165; b) P. T. Anastas, M. M. Kirchhoff, T. C. Williamson, Appl. Catal. A Gen. 2001, 
221, 3–13; c) B. M. Trost, Science 1991, 254, 1471–1477. 
[103] a) P. T. Anastas, M. M. Kirchhoff, Acc. Chem. Res. 2002, 35, 686–694; b) J. A. Linthorst, Found. Chem. 2010, 12, 55–68. 
[104] a) Y. Ni, D. Holtmann, F. Hollmann, ChemCatChem 2014, 6, 930–943; b) R. A. Sheldon, J. M. Woodley, Chem. Rev. 2018, 118, 801–
838. 
[105] a) A. J. J. Straathof, S. Panke, A. Schmid, Curr. Opin. Biotechnol. 2002, 13, 548–556; b) R. A. Sheldon, D. Brady, M. L. Bode, Chem. 
Sci. 2020, 11, 2587–2605; c) J. M. Woodley, Appl. Microbiol. Biotechnol. 2019, 103, 4733–4739. 
[106] F. Balkenhohl, K. Ditrich, B. Hauer, B. Aktiengesellschaft, J. für Prakt. Chemie 1997, 339, 381–384. 
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
39 
 
[107] M. T. Reetz, J. Am. Chem. Soc. 2013, 135, 12480–12496. 
[108] a) M. Breuer, K. Ditrich, T. Habicher, B. Hauer, M. Keßeler, R. Stürmer, T. Zelinski, Angew. Chemie - Int. Ed. 2004, 43, 788–824; b) 
A. Basso, S. Serban, Mol. Catal. 2019, 479, 110607. 
[109] a) G. Qu, A. Li, C. G. Acevedo-Rocha, Z. Sun, M. T. Reetz, Angew. Chemie - Int. Ed. 2020, 59, 13204–13231; b) M. T. Reetz, Angew. 
Chemie - Int. Ed. 2011, 50, 138–174. 
[110] C. A. Voigt, C. Martinez, Z. G. Wang, S. L. Mayo, F. H. Arnold, Nat. Struct. Biol. 2002, 9, 553–558. 
[111] A. S. Bommarius, J. K. Blum, M. J. Abrahamson, Curr. Opin. Chem. Biol. 2011, 15, 194–200. 
[112] J. K. Leman, B. D. Weitzner, S. M. Lewis, J. Adolf-Bryfogle, N. Alam, R. F. Alford, M. Aprahamian, D. Baker, K. A. Barlow, P. Barth, 
B. Basanta, B. J. Bender, K. Blacklock, J. Bonet, S. E. Boyken, P. Bradley, C. Bystroff, P. Conway, S. Cooper, B. E. Correia, B. Coventry, 
R. Das, R. M. De Jong, F. DiMaio, L. Dsilva, R. Dunbrack, A. S. Ford, B. Frenz, D. Y. Fu, C. Geniesse, L. Goldschmidt, R. Gowthaman, 
J. J. Gray, D. Gront, S. Guffy, S. Horowitz, P. S. Huang, T. Huber, T. M. Jacobs, J. R. Jeliazkov, D. K. Johnson, K. Kappel, J. Karanicolas, 
H. Khakzad, K. R. Khar, S. D. Khare, F. Khatib, A. Khramushin, I. C. King, R. Kleffner, B. Koepnick, T. Kortemme, G. Kuenze, B. 
Kuhlman, D. Kuroda, J. W. Labonte, J. K. Lai, G. Lapidoth, A. Leaver-Fay, S. Lindert, T. Linsky, N. London, J. H. Lubin, S. Lyskov, J. 
Maguire, L. Malmström, E. Marcos, O. Marcu, N. A. Marze, J. Meiler, R. Moretti, V. K. Mulligan, S. Nerli, C. Norn, S. Ó’Conchúir, N. 
Ollikainen, S. Ovchinnikov, M. S. Pacella, X. Pan, H. Park, R. E. Pavlovicz, M. Pethe, B. G. Pierce, K. B. Pilla, B. Raveh, P. D. Renfrew, 
S. S. R. Burman, A. Rubenstein, M. F. Sauer, A. Scheck, W. Schief, O. Schueler-Furman, Y. Sedan, A. M. Sevy, N. G. Sgourakis, L. Shi, 
J. B. Siegel, D. A. Silva, S. Smith, Y. Song, A. Stein, M. Szegedy, F. D. Teets, S. B. Thyme, R. Y. R. Wang, A. Watkins, L. Zimmerman, 
R. Bonneau, Nat. Methods 2020, 17, 665–680. 
[113] M. T. Reetz, J. D. Carballeira, A. Vogel, Angew. Chemie - Int. Ed. 2006, 45, 7745–7751. 
[114] P. A. Dalby, Curr. Opin. Struct. Biol. 2011, 21, 473–480. 
[115] a) R. E. Cobb, T. Si, H. Zhao, Curr. Opin. Chem. Biol. 2012, 16, 285–291; b) J. C. Moore, A. Rodriguez-Granillo, A. Crespo, S. 
Govindarajan, M. Welch, K. Hiraga, K. Lexa, N. Marshall, M. D. Truppo, ACS Synth. Biol. 2018, 7, 1730–1741. 
[116] a) M. T. Reetz, M. Bocola, J. D. Carballeira, D. Zha, A. Vogel, Angew. Chemie - Int. Ed. 2005, 44, 4192–4196; b) M. T. Reetz, L. W. 
Wang, M. Bocola, Angew. Chemie - Int. Ed. 2006, 45, 1236–1241; c) M. T. Reetz, J. D. Carballeira, J. Peyralans, H. Höbenreich, A. 
Maichele, A. Vogel, Chem. - A Eur. J. 2006, 12, 6031–6038. 
[117] M. T. Reetz, Chem. Rec. 2016, 16, 2449–2459. 
[118] a) M. J. Abrahamson, E. Vázquez-Figueroa, N. B. Woodall, J. C. Moore, A. S. Bommarius, Angew. Chemie - Int. Ed. 2012, 51, 3969–
3972; b) M. J. Abrahamson, J. W. Wong, A. S. Bommarius, Adv. Synth. Catal. 2013, 355, 1780–1786; c) B. R. Bommarius, M. 
Schürmann, A. S. Bommarius, Chem. Commun. 2014, 50, 14953–14955. 
[119] M. T. Reetz, S. Prasad, J. D. Carballeira, Y. Gumulya, M. Bocola, J. Am. Chem. Soc. 2010, 132, 9144–9152. 
[120] K. K. Yang, Z. Wu, F. H. Arnold, Nat. Methods 2019, 16, 687–694. 
[121] R. Fox, J. Theor. Biol. 2005, 234, 187–199. 
[122] R. J. Fox, S. C. Davis, E. C. Mundorff, L. M. Newman, V. Gavrilovic, S. K. Ma, L. M. Chung, C. Ching, S. Tam, S. Muley, J. Grate, J. 
Gruber, J. C. Whitman, R. A. Sheldon, G. W. Huisman, Nat. Biotechnol. 2007, 25, 338–344. 
[123] C. K. Savile, J. M. Janey, E. C. Mundorff, J. C. Moore, S. Tam, W. R. Jarvis, J. C. Colbeck, A. Krebber, F. J. Fleitz, J. Brands, P. N. Devine, 
G. W. Huisman, G. J. Hughes, Science 2010, 329, 305–310. 
[124] M. Schober, C. MacDermaid, A. A. Ollis, S. Chang, D. Khan, J. Hosford, J. Latham, L. A. F. Ihnken, M. J. B. Brown, D. Fuerst, M. J. 
Sanganee, G. D. Roiban, Nat. Catal. 2019, 2, 909–915. 
[125] G. D. Roiban, M. Kern, Z. Liu, J. Hyslop, P. L. Tey, M. S. Levine, L. S. Jordan, K. K. Brown, T. Hadi, L. A. F. Ihnken, M. J. B. Brown, 
ChemCatChem 2017, 9, 4475–4479. 
[126] S. B. J. Kan, R. D. Lewis, K. Chen, F. H. Arnold, Science 2016, 354, 1048–1051. 
[127] S. F. Altschul, W. Gish, W. Miller, E. W. Myers, D. J. Lipman, J. Mol. Biol. 1990, 215, 403–410. 
[128] J. Jiang, X. Chen, D. Zhang, Q. Wu, D. Zhu, Appl. Microbiol. Biotechnol. 2015, 99, 2613–2621. 
[129] F. Steffen-Munsberg, C. Vickers, A. Thontowi, S. Schätzle, T. Tumlirsch, M. SvedendahlHumble, H. Land, P. Berglund, U. T. 
Bornscheuer, M. Höhne, ChemCatChem 2013, 5, 150–153. 
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
40 
 
[130] J. Britton, S. Majumdar, G. A. Weiss, Chem. Soc. Rev. 2018, 47, 5891–5918. 
[131] M. Romero-Fernández, F. Paradisi, in Catal. Immobil. Methods Appl. (Eds.: M. Benaglia, A. Puglisi), 2020, pp. 409–435. 
[132] M. Thompson, I. Penafiel, S. C. Cosgrove, N. J. Turner, Org. Process Res. Dev. 2018, acs.oprd.8b00305. 
[133] J. M. Guisan, Ed. , Immobilization of Enzymes and Cells, Humana Press Inc., 2013. 
[134] R. A. Sheldon, Adv. Synth. Catal. 2007, 349, 1289–1307. 
[135] E. Hochuli, W. Bannwarth, H. Döbeli, Nat. Biotechnol. 1988, 6, 1321–1325. 
[136] a) K. Engelmark Cassimjee, M. Kadow, Y. Wikmark, M. Svedendahl Humble, M. L. Rothstein, D. M. Rothstein, J. E. Bäckvall, Chem. 
Commun. 2014, 50, 9134–9137; b) W. Böhmer, A. Volkov, K. Engelmark Cassimjee, F. G. Mutti, Adv. Synth. Catal. 2020, 362, 1858-
1867. 
[137] W. Böhmer, T. Knaus, A. Volkov, T. K. Slot, N. R. Shiju, K. Engelmark Cassimjee, F. G. Mutti, J. Biotechnol. 2019, 291, 52–60. 
[138] a) M. Planchestainer, D. R. Padrosa, M. L. Contente, F. Paradisi, Catalysts 2018, 8, 40; b) D. R. Padrosa, V. De Vitis, M. L. Contente, 
F. Molinari, F. Paradisi, Catalysts 2019, 9, 232. 
[139] a) G. P. Anderson, J. L. Liu, L. C. Shriver-Lake, D. Zabetakis, V. A. Sugiharto, H. W. Chen, C. R. Lee, G. N. Defang, S. J. L. Wu, N. 
Venkateswaran, E. R. Goldman, Anal. Chem. 2019, 91, 9424–9429; b) J. X. Wong, M. Gonzalez-Miro, A. J. Sutherland-Smith, B. H. 
A. Rehm, Front. Bioeng. Biotechnol. 2020, 8, 1–19. 
[140] V. J. Jensen, S. Rugh, Methods Enzymol. 1987, 136, 356–370. 
[141] J. H. Schrittwieser, S. Velikogne, M. Hall, W. Kroutil, Chem. Rev. 2018, 118, 270–348. 
[142] M. L. Contente, F. Paradisi, Nat. Catal. 2018, 1, 452–459. 
[143] A. W. H. Dawood, J. Bassut, R. O. M. A. de Souza, U. Bornscheuer, Chem. - A Eur. J. 2018, 24, 16009–16013. 
[144] J. Latham, J. M. Henry, H. H. Sharif, B. R. K. Menon, S. A. Shepherd, M. F. Greaney, J. Micklefield, Nat. Commun. 2016, 7, 1–8. 
[145] M. A. Huffman, A. Fryszkowska, O. Alvizo, M. Borra-Garske, K. R. Campos, K. A. Canada, P. N. Devine, D. Duan, J. H. Forstater, S. T. 
Grosser, H. M. Halsey, G. J. Hughes, J. Jo, L. A. Joyce, J. N. Kolev, J. Liang, K. M. Maloney, B. F. Mann, N. M. Marshall, M. McLaughlin, 
J. C. Moore, G. S. Murphy, C. C. Nawrat, J. Nazor, S. Novick, N. R. Patel, A. Rodriguez-Granillo, S. A. Robaire, E. C. Sherer, M. D. 
Truppo, A. M. Whittaker, D. Verma, L. Xiao, Y. Xu, H. Yang, Science 2019, 366, 1255–1259. 
[146] K. Fukuyama, H. Ohrui, S. Kuwahara, Org. Lett. 2015, 17, 828–831. 
[147] S. Mazurenko, Z. Prokop, J. Damborsky, ACS Catal. 2020, 10, 1210–1223. 
[148] J. Hon, S. Borko, J. Stourac, Z. Prokop, J. Zendulka, D. Bednar, T. Martinek, J. Damborsky, Nucleic Acids Res. 2020, 48, W104–W109. 
[149] O. Vavra, J. Filipovic, J. Plhak, D. Bednar, S. M. Marques, J. Brezovsky, J. Stourac, L. Matyska, J. Damborsky, Bioinformatics 2019, 
35, 4986–4993. 
[150] a) C. Zeymer, D. Hilvert, Annu. Rev. Biochem 2018, 87, 131–157; b) J. B. Siegel, A. Zanghellini, H. M. Lovick, G. Kiss, A. R. Lambert, 
J. L. S. Clair, J. L. Gallaher, D. Hilvert, M. H. Gelb, B. L. Stoddard, K. N. Houk, F. E. Michael, D. Baker, Science 2010, 329, 309–313; c) 
R. Obexer, A. Godina, X. Garrabou, P. R. E. Mittl, D. Baker, A. D. Griffiths, D. Hilvert, Nat. Chem. 2017, 9, 50–56; d) D. S. Macdonald, 
X. Garrabou, C. Klaus, R. Verez, T. Mori, D. Hilvert, J. Am. Chem. Soc. 2020, 142, 10250–10254;  
[151] I. Drienovská, G. Roelfes, Nat. Catal. 2020, 3, 193–202. 
[152] J. D. Keasling, Metab. Eng. 2012, 14, 189–195. 
[153] a) H. Schwarz, M. Schmittner, A. Duschl, J. Horejs-Hoeck, PLoS ONE 2014, 9, e113840; b) U. Mamat, K. Wilke, D. Bramhill, A. B. 
Schromm, B. Lindner, T. A. Kohl, J. L. Corchero, A. Villaverde, L. Schaffer, S. R. Head, C. Souvignier, T. C. Meredith, R. W. Woodard, 
Microb. Cell Factories 2015, 14, 1–15. 
[154] a) F. J. Fernández, M. C. Vega, in Advanced Technologies for Protein Complex Production and Characterization. Advances in 
Experimental Medicine and Biology (Ed.: M.C. Vega), Springer, Cham, Heidelberg, 2016, pp. 15–24; b) T. Allers, Bioeng. Bugs 2010, 
1, 290–292; c) M. W. Larsen, U. T. Bornscheuer, K. Hult, Protein Expr. Purif. 2008, 62, 90–97; d) K. Terpe, Appl. Microbiol. 
Biotechnol. 2006, 72, 211–222. 
[155] B. Hauer, ACS Catal. 2020, 10, 8418–8427. 
10.1002/cctc.202001107
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
41 
 
Entry for the Table of Contents 
 
In this historical review we highlight the developments across several fields that were necessary to create the 
modern field of biocatalysis and showcase the resulting examples of cutting-edge enzymatic applications in 
industry. 
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